THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN.L, AZN) and Amgen, Inc. (AMGN) announced Thursday the availability of Tezspire (tezepelumab-ekko) for shipment to wholesalers in the US.
Tezspire was approved by the U.S. Food and Drug Administration (FDA) on December 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX